Sugi Predict

Sugi Predict / Compounds / SCHEMBL2720

SCHEMBL2720

SCHEMBL2720

CNC(=S)NC(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 4/20 0.41
▸ CA1 P00915 4/20 0.37
▸ CA2 P00918 4/20 0.37
▸ CA12 O43570 4/20 0.37
▸ CA9 Q16790 2/20 0.37
▸ TDP1 Q9NUW8 1/20 0.36
▸ NFKB1 P19838 1/20 0.36
▸ NFKB2 Q00653 1/20 0.36
▸ RELA Q04206 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ DGAT1 O75907 1/20 0.35
▸ CA7 P43166 2/20 0.35
▸ EPHX1 P07099 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ CA14 Q9ULX7 2/20 0.33
▸ APLNR P35414 1/20 0.33
▸ RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL151345 0.89 GAA (0.44) GAACA1CA2CA12CA9
SCHEMBL15756433 0.81 GAA (0.40) GAACA1CA2CA12CA9
SCHEMBL11967258 0.81 EPHX1 (0.52) GAACA1CA2CA12CA9
SCHEMBL101218 0.78 DGAT1 (0.46) GAACA1CA2CA12TDP1
SCHEMBL287599 0.78 ALDH1A1 (0.44) GAACA1CA2CA12CA9
SCHEMBL9923753 0.77 GAA (0.40) GAACA1CA2CA12CA9
SCHEMBL12246341 0.77 CA1 (0.39) GAACA1CA2CA12TDP1
SCHEMBL21431057 0.76 CTSK (0.39) GAACA1CA2CA12CA9
SCHEMBL1522412 0.76 DGAT1 (0.44) GAACA1CA2CA12TDP1
SCHEMBL6272856 0.76 DGAT1 (0.44) GAACA1CA2CA12TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023209728-A1 SYNTHETIC CATIONIC PEPTIDOMIMETICS, THEIR DERIVATIVES AND PREPARATION THEREOF ALONG WITH COMPOSITIONS FOR VARIOUS MEDICAL APPLICATIONS PEPTOMER THERAPEUTICS PRIVATE LIMITED (IN) 2023-11-02 — — WO disclosed
EP-3250035-B1 COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS ALLGENESIS BIOTHERAPEUTICS INC (TW) 2023-01-25 — — EP disclosed
US-11136310-B2 Iminotetrahydropyrimidinone derivatives as plasmepsin V inhibitors UCB Biopharma SRL (BE) 2021-10-05 — — US disclosed
US-10870635-B2 Compounds and their use as BACE1 inhibitors ALLGENESIS BIOTHERAPEUTICS, INC. (TW) 2020-12-22 — — US disclosed
US-10870635-B2 Compounds and their use as BACE1 inhibitors ALLGENESIS BIOTHERAPEUTICS, INC. (TW) 2020-12-22 — — US disclosed
CN-107613771-B Compounds and their use as beta-secretase 1 inhibitors 新源生物科技股份有限公司 2020-12-15 — — CN disclosed
US-20200283416-A1 IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS CELLTECH R&D LIMITED (GB) 2020-09-10 — — US disclosed
EP-3223820-B1 3-METHYL-2-IMINO-HEXAHYDRO-1H-PYRANO[3,4-D]PYRIMIDIN-4-ONE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME (US) 2020-07-22 — — EP disclosed
EP-3380464-B1 IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS UCB Biopharma SRL (BE) 2020-05-27 — — EP disclosed
EP-1891021-B1 ASPARTYL PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2019-01-23 — — EP disclosed
US-20070060575-A1 Aspartyl protease inhibitors MERCK SHARP & DOHME LLC 2007-03-15 — — US disclosed
US-20070060575-A1 Aspartyl protease inhibitors MERCK SHARP & DOHME LLC 2007-03-15 — — US disclosed
WO-2006138265-A2 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS, PREPARATION AND USE THEREOF SCHERING CORPORATION (US) 2006-12-28 — — WO disclosed
WO-2006138265-A2 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS, PREPARATION AND USE THEREOF SCHERING CORPORATION (US) 2006-12-28 — — WO disclosed
WO-2006138264-A2 ASPARTYL PROTEASE INHIBITORS SCHERING CORPORATION (US) 2006-12-28 — — WO disclosed
WO-2006138264-A2 ASPARTYL PROTEASE INHIBITORS SCHERING CORPORATION (US) 2006-12-28 — — WO disclosed
US-20060287294-A1 Aspartyl protease inhibitors MERCK SHARP & DOHME LLC 2006-12-21 — — US disclosed
WO-2006065277-A2 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS SCHERING CORPORATION (US) 2006-06-22 — — WO disclosed
WO-2006065277-A2 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS SCHERING CORPORATION (US) 2006-06-22 — — WO disclosed
US-20060111370-A1 Heterocyclic aspartyl protease inhibitors SCHERING CORPORATION 2006-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10870635-B2 Compounds and their use as BACE1 inhibitors BACE1, BACE2, APP GAA 34/4885CA1 3229/4885CA2 3271/4885
US-20070060575-A1 Aspartyl protease inhibitors CHRM2, BACE1, CHRM1 GAA 491/4885CA1 248/4885CA2 1460/4885
US-20200283416-A1 IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS PEPD, ADAM17, ANPEP GAA 2807/4885CA1 3579/4885CA2 2690/4885
US-20060111370-A1 Heterocyclic aspartyl protease inhibitors CHRM1, CHRM2, PRSS1 GAA 1474/4885CA1 302/4885CA2 1310/4885
US-20060287294-A1 Aspartyl protease inhibitors CHRM1, BACE1, CHRM2 GAA 413/4885CA1 203/4885CA2 1636/4885
US-11136310-B2 Iminotetrahydropyrimidinone derivatives as plasmepsin V inhibitors PEPD, ADAM17, ANPEP GAA 2807/4885CA1 3579/4885CA2 2690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.